<DOC>
	<DOC>NCT01597258</DOC>
	<brief_summary>The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.</brief_summary>
	<brief_title>Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan)</brief_title>
	<detailed_description>All the patients whom an investigator prescribes Crizotinib (XALKORI) should be registered.</detailed_description>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>All the patients whom an investigator prescribes XALKORI. (Patients need to be administered Crizotinib (XALKORI) in order to be enrolled in this all cases surveillance.) Patients not administered XALKORI in spite of enrolled.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Safety</keyword>
	<keyword>All cases surveillance in Japan</keyword>
	<keyword>ALK-positive unresectable advanced and/or recurrent non-small cell lung cancer</keyword>
</DOC>